Multiple-variable dose regimen for TNFα inhibitor therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TNFα-related disorders, such as Crohn's disease and psoriasis, are not entirely effective in abating inflammatory processes and often come with significant side effects, necessitating a safer and more effective therapeutic approach.
Innovation Solution
A multiple-variable dose method involving the administration of TNFα inhibitors, specifically etanercept or infliximab, with induction and treatment phases to achieve and maintain therapeutic thresholds, utilizing antibodies like D2E7 that dissociate slowly from TNFα and effectively neutralize its cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for TNFα-related disorders are used, then some therapeutic effect is achieved, but significant side effects occur and complete abatement of inflammatory processes is not achieved
Solution Approach 1:
The patent applies parameter changes by implementing a multiple-variable dose regimen that adjusts the dosage of TNFα inhibitors based on individual patient response and disease severity. This includes varying induction doses, maintenance doses, and dosing intervals to optimize therapeutic effectiveness while minimizing side effects, directly addressing the contradiction between reliability and harmful factors
2Reliability
If current treatments for TNFα-related disorders are used, then some inflammatory process is reduced, but complete abatement is not achieved
Solution Approach 1:
The patent implements dynamics by using adaptive dose adjustment strategies where the treatment regimen evolves based on patient response. The induction phase uses higher doses to rapidly reduce inflammation, followed by tailored maintenance dosing that dynamically adjusts based on clinical outcomes, enabling complete inflammatory abatement while managing complexity through structured adaptability
3Object-affected harmful factors
If rotation of systemic therapies is used to avoid cumulative toxic effects, then side effects are managed, but treatment continuity and effectiveness are compromised
Solution Approach 1:
The patent applies continuity of useful action by establishing structured maintenance dosing regimens that provide continuous therapeutic coverage after the induction phase. Rather than rotating treatments, the regimen maintains consistent TNFα inhibition through scheduled dosing intervals, ensuring treatment continuity while managing toxicity through predictable, manageable dosing rather than abrupt therapy changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method induces remission in Crohn's disease, reduces psoriatic plaques, and provides therapeutic benefits with reduced side effects by carefully managing TNFα inhibitor dosage, improving patient outcomes for TNFα-related disorders.
Implementation Method 1
utilizing antibodies like D2E7 that dissociate slowly from TNFα and effectively neutralize its cytotoxicity
Data Source
AI summary
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.